Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated With Ipilimumab

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p96
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab

Journal of Cutaneous Immunology and Allergy
2019English

Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma

Cancer immunology research
Cancer ResearchImmunology
2014English

Corrigendum: Association of CTLA-4 Gene Variants With Response to Therapy and Long-Term Survival in Metastatic Melanoma Patients Treated With Ipilimumab: An Italian Melanoma Intergroup Study

Frontiers in Immunology
AllergyImmunology
2018English

Imaging Biomarkers of Adiposity and Sarcopenia as Potential Predictors for Overall Survival Among Patients With Endometrial Cancer Treated With Bevacizumab

Gynecologic Oncology
GynecologyOncologyObstetrics
2017English

Hypertension and Overall Survival in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Containing Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2011English

Predictors of Overall Survival Among Patients Treated With Sirolimus/Tacrolimus vs Methotrexate/Tacrolimus for GvHD Prevention

Bone Marrow Transplantation
TransplantationHematology
2017English

Long Bone Metastases as Predictors of Survival in Patients With Metastatic Renal Cancer

Nuclear Medicine Review
MedicineNuclear MedicineRadiologyImaging
2015English

Impact of Clinicopathological Characteristics on Survival in Patients Treated With Immune Checkpoint Inhibitors for Metastatic Melanoma

International Journal of Cancer
Cancer ResearchOncology
2018English

Linking Tumor Growth Dynamics to Survival in Ipilimumab‐Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling

CPT: Pharmacometrics and Systems Pharmacology
ModelingSimulationCardiovascular MedicinePharmacologyCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy